CN1175879C - 一种治疗晚期癌症痛苦综合症的药物 - Google Patents
一种治疗晚期癌症痛苦综合症的药物 Download PDFInfo
- Publication number
- CN1175879C CN1175879C CNB021387346A CN02138734A CN1175879C CN 1175879 C CN1175879 C CN 1175879C CN B021387346 A CNB021387346 A CN B021387346A CN 02138734 A CN02138734 A CN 02138734A CN 1175879 C CN1175879 C CN 1175879C
- Authority
- CN
- China
- Prior art keywords
- gram
- grams
- medicine
- radix
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 201000011510 cancer Diseases 0.000 title claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 16
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 title abstract description 9
- 208000002193 Pain Diseases 0.000 title abstract description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000002775 capsule Substances 0.000 claims abstract description 13
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 10
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 9
- 229960000905 indomethacin Drugs 0.000 claims abstract description 9
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims abstract description 7
- 229960002256 spironolactone Drugs 0.000 claims abstract description 7
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001596 famotidine Drugs 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 241000600871 Euryale <brittle star> Species 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 241000756943 Codonopsis Species 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229940126678 chinese medicines Drugs 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000208365 Celastraceae Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 244000268590 Euryale ferox Species 0.000 abstract 1
- 241000212941 Glehnia Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 241000208966 Polygala Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 1
- 208000004880 Polyuria Diseases 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 235000000336 Solanum dulcamara Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 229960003529 diazepam Drugs 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000035619 diuresis Effects 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 238000007654 immersion Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗晚期癌症痛苦综合症的药物及其制法。该药采用中西药结合的方式，其配方包含黄芪、女贞子、制黄精、北沙参、麦冬、党参、白术、茯苓、绞股蓝、白英、仙鹤草、山药、芡实、制陈皮、去心远志、甘草、吲哚美辛、地塞米松、螺内酯、法莫替丁、安定。上述药物经浸泡、煎煮、过滤、干燥后制成成药——志苓丹胶囊。临床证明该药具有抗癌、消炎、镇痛、利水、提高机体免疫功能，能有效地抑制癌细胞的迅猛增长，并较全面减轻晚期癌症患者的各种痛苦，提高生存质量，延长生命。
Description
技术领域：
本发明涉及一种抗癌药物及其制法，具体地说是提供一种治疗晚期癌症痛苦综合症的药物及其制法。
背景技术：
癌症是危害人类健康的常见病，由于早期发现较困难，病人就诊时大都是发展到中晚期。有些病例虽经过手术、放、化疗缓解一段，但到复发或转移后，仍要经过晚期的痛苦综合症，诸如疼痛、发烧、咳嗽、气喘、吞咽困难、炎症、水肿、食欲不振、失眠、焦虑、惊恐、烦躁不安等病症困扰着病人。多数患者都在痛苦煎熬中艰难地走到生命的尽头。当今国内外尚无一种药物能够同时全面有效的解决晚期癌症上述的痛苦综合症。
发明内容：
本发明的目的是提供一种治疗晚期癌症痛苦综合征的药物及其制法。发明人通过多年临床实践结合动物实验，筛选研制出一种中西药结合的方剂——志苓丹胶囊，能有效地抑制癌细胞的迅猛增长，并较全面减轻晚期癌症患者的各种痛苦，提高生存质量，延长生命。
本发明的目的是通过以下技术方案实现的：一种治疗晚期癌症痛苦综合征的药物，该药物由16味中药和5种西药制成，每一千粒胶囊配方中含有中药成分：黄芪100-300克、女贞子100-300克、制黄精100-300克、北沙参100-250克、麦冬100-300克、党参100-250克、白术100-250克、茯苓100-250克、绞股蓝100-250克、白英100-300克、仙鹤草100-300克、山药100-250克、芡实100-300克、制陈皮100-250克、去心远志100-250克、甘草30-80克；同时还含有西药成分：吲哚美辛5-22克、地塞米松100-500毫克、螺内酯4-20克、法莫替丁3-15克、安定0.2-2.0克。
该药物的制备方法是：在上述16味中药中取芡实、山药两味半量分别磨细粉混合备用，取白英、仙鹤草、女贞子3味，加入8倍量70％乙醇加热回流提取1.5小时，滤过，滤液回收乙醇成清膏另存；余下13味药材加10倍量水浸泡1小时后，加入经乙醇提后的药渣，煎煮2次(每次1.5小时)，合并煎液，滤过，滤液浓缩成清膏，将水煮清膏与醇提膏合并，于＜80℃干燥成干浸膏，粉碎成细粉，与芡实、山药混合细粉混匀；之后5种西药细粉以等量递增法混合均匀制粒，分装，制成1000粒胶囊。
本方了黄芪、女贞子补益脾肺，滋养肝肾为君药；用黄精、北沙参、麦冬润肺滋肾；党参、山药、白术、茯苓健脾宁心；白英、仙鹤草清热解毒为臣药，增强君药扶正培本、清热解毒、气阴双补之力；以绞股蓝、芡实、陈皮、远志扶脾和胃、理气化痰，祛邪安正为佐；使以甘草甘缓益气、调和诸药。综合诸药性能，共起补益气阴，滋养肝肾，健脾解毒，扶正抗癌之功。再配合西药吲哚美辛、地塞米松、螺内酯具有解热镇痛、消炎解毒、利水抗癌。对中晚期癌症的常见症状，如痛、热、炎、肿等疗效确切，与16味中药结合效果倍增而稳妥。方中地塞米松、吲哚美辛有损害胃肠粘膜，容易导致溃疡、法莫替丁及志苓丹胶囊中的中药成分，有明显保护胃肠粘膜、抗溃疡的作用，中西药结合可防止胃溃疡的发生。安定能解除癌症病人的精神紧张和焦虑，并有镇静安眠的作用，与安神宁心的中药结合，有协同作用。地塞米松有抑制免疫，吲哚美辛能提高免疫，一抑一扬可互相抵消。螺内酯有抗癌利水之功，对癌症或其周围炎症性充血水肿或胸腹水者亦有缓解作用，与地塞米松、吲哚美辛配合，相得益彰。
通过全国6家国家药品临床试验基地验证，证明该药物——志苓丹胶囊对癌症的气阴两虚症候(包括上述痛苦综合症)有效率达91.3％；对照组1志苓丹胶囊中5种纯西药成分有效率50.0％；对照组2志苓丹胶囊中16种中药成分有效率36.6％；对照组3平消胶囊有效率14％；证明志苓丹胶囊明显优于对照组，体现中西结合复方制剂的优势。
具体实施方式：
以下是本药物配方的最佳实施例：黄芪166.7克、女贞子166.7克、制黄精166.7克、北沙参138.9克、麦冬166.7克、党参138.9克、白术138.9克、茯苓138.9克、绞股蓝138.9克、白英166.7克、仙鹤草166.7克、山药138.9克、芡实166.7克、制陈皮138.9克、去心远志138.9克、甘草41.7克、吲哚美辛11.11克、地塞米松244毫克、螺内酯5.55克、法莫替丁6.5克、安定0.55克。按前述的制备方法可制得成药——志苓丹胶囊。
Claims (2)
1、一种治疗晚期癌症痛苦综合症的药物，其特征在于每一千粒胶囊由以下重量配比的16味中药和5种西药制成：黄芪100-300克、女贞子100-300克、制黄精100-300克、北沙参100-250克、麦冬100-300克、党参100-250克、白 术100-250克、茯苓100-250克、绞股蓝100-250克、白英100-300克、仙鹤草100-300克、山药100-250克、芡实100-300克、制陈皮100-250克、去心远志100-250克、甘草30-80克；吲哚美辛5-22克、地塞米松100-500毫克、螺内酯4-20克、法莫替丁3-15克、安定0.2-2.0克，其制备方法为：取芡实、山药两味半量分别磨细粉混合备用，取白英、仙鹤草、女贞子3味，加入8倍量70％乙醇加热回流提取1.5小时，滤过，滤液回收乙醇成清膏另存；余下13味药材加10倍量水浸泡1小时后，加入经乙醇提后的药渣，煎煮2次，每次1.5小时，合并煎液，滤过，滤液浓缩成清膏，将水煮清膏与醇提膏合并，于＜80℃干燥成干浸膏，粉碎成细粉，与芡实、山药混合细粉混匀；之后5种西药细粉以等量递增法混合均匀制粒，分装于胶囊，制成1000粒胶囊。
2、根据权利要求1所述的一种治疗晚期癌症痛苦综合症的药物，其特征在于该药物的原料配比为：黄芪166.7克、女贞子166.7克、制黄精166.7克、北沙参138.9克、麦冬166.7克、党参138.9克、白术138.9克、茯苓138.9克、绞股蓝138.9克、白英166.7克、仙鹤草166.7克、山药138.9克、芡实166.7克、制陈皮138.9克、去心远志138.9克、甘草41.7克、吲哚美辛11.11克、地塞米松244毫克、螺内酯5.55克、法莫替丁6.5克、安定0.55克。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021387346A CN1175879C (zh) | 2002-06-27 | 2002-06-27 | 一种治疗晚期癌症痛苦综合症的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021387346A CN1175879C (zh) | 2002-06-27 | 2002-06-27 | 一种治疗晚期癌症痛苦综合症的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1391952A CN1391952A (zh) | 2003-01-22 |
| CN1175879C true CN1175879C (zh) | 2004-11-17 |
Family
ID=4749669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021387346A Expired - Lifetime CN1175879C (zh) | 2002-06-27 | 2002-06-27 | 一种治疗晚期癌症痛苦综合症的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1175879C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021255438A1 (en) * | 2020-06-16 | 2021-12-23 | Imaginatives Group Limited | Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100423779C (zh) * | 2006-09-27 | 2008-10-08 | 中国药科大学 | 一种以5－羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途 |
| GB201317373D0 (en) | 2013-10-01 | 2013-11-13 | Univ Dundee | Treatment and prevention of cancer |
| CN105311273A (zh) * | 2015-11-26 | 2016-02-10 | 青岛海之源智能技术有限公司 | 一种法莫替丁复方缓释片及其制备方法 |
-
2002
- 2002-06-27 CN CNB021387346A patent/CN1175879C/zh not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021255438A1 (en) * | 2020-06-16 | 2021-12-23 | Imaginatives Group Limited | Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1391952A (zh) | 2003-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111481648B (zh) | 一种健脾养胃中药组合物及中药制剂 | |
| CN105535471A (zh) | 一种用于治疗神经衰弱的丸剂药物及其制备方法 | |
| CN112006137A (zh) | 一种健脾养胃苏菔茶及其制备方法 | |
| CN104971215A (zh) | 一种治疗脾虚胃弱型慢性胃炎的中药组合物及其制备方法 | |
| CN105106885A (zh) | 降逆止痛养胃汤 | |
| CN104940596A (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
| CN102205059A (zh) | 一种治疗肝、胃、肺、血癌的中草药组合物及制备方法 | |
| CN1175879C (zh) | 一种治疗晚期癌症痛苦综合症的药物 | |
| CN107184750B (zh) | 治疗慢性肾小球肾炎、肾病综合征的药物及其制备方法 | |
| CN1056064C (zh) | 一种治疗肝癌的药物及其制造方法 | |
| CN104958636A (zh) | 一种治疗功能性消化不良的药物组合物及其制备方法 | |
| CN1408383A (zh) | 一种治疗胃肠癌的纯中药制剂及制备方法 | |
| CN104771697A (zh) | 一种治疗胆囊炎的药物组合物 | |
| CN104189764A (zh) | 一种治疗介入术后发热的中药制剂及其制备方法 | |
| CN103877483A (zh) | 一种治疗慢性胃炎的中药及其制备方法 | |
| CN103223024A (zh) | 糖尿病辩证的中药方剂 | |
| CN101167921A (zh) | 一种治疗胃痛的药物组合物及其制备方法 | |
| CN113797294A (zh) | 一种治疗萎缩性胃炎的药物组合物及制备方法 | |
| CN102755519B (zh) | 葛根葛花抗口腔溃疡颗粒及其制备方法 | |
| CN105770673A (zh) | 一种含艾叶的中药制剂用于制备治疗慢性胃炎药物中的用途 | |
| CN105288128A (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
| CN104998225A (zh) | 一种治疗便秘的药物制剂 | |
| CN1062176C (zh) | 一种治疗癌症的口服液 | |
| CN104399036A (zh) | 一种治疗慢性腹泻的药物组合物及其应用 | |
| CN1166971A (zh) | 止泻冲剂及其制作方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: PAN YUANZHI Free format text: FORMER OWNER: PAN MINGJI Effective date: 20120919 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 350009 FUZHOU, FUJIAN PROVINCE TO: 350001 FUZHOU, FUJIAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120919 Address after: 350001, 1402, Rongcheng business center, No. 129 Wuyi Road, Fujian, Fuzhou Patentee after: Pan Yuanzhi Address before: 350009 Fuzhou first hospital, 190 Da Dao, Fujian, Fuzhou Patentee before: Pan Mingji |
|
| DD01 | Delivery of document by public notice |
Addressee: Pan Yuanzhi Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| CX01 | Expiry of patent term |
Granted publication date: 20041117 |
|
| CX01 | Expiry of patent term |